← Back to Search

F18 Florbetapir (amyvid) cardiac PET/CT imaging for Cardiac Amyloidosis

Phase 4
Waitlist Available
Led By Chris Mueller, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial will test if a chemotherapy regimen can reduce the amount of amyloid protein in the heart of patients with AL amyloidosis.

Eligible Conditions
  • Cardiac Amyloidosis


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Relative change in cardiac uptake of 18F florbetapir prior to chemotherapy and after six months of chemotherapy.
Secondary outcome measures
Cardiac response
Hematologic response
Patient related outcomes
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with AL cardiac amyloidExperimental Treatment1 Intervention
Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
610 Previous Clinical Trials
1,162,710 Total Patients Enrolled
Chris Mueller, MDPrincipal InvestigatorMedical College of Wisconsin

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA endorsed F18 Florbetapir (amyvid) for cardiac PET/CT imaging?

"Data collected from Phase 4 trials has provided evidence that F18 Florbetapir (amyvid) cardiac PET/CT imaging is a safe treatment, leading to its rating of 3 out of 3."

Answered by AI

Are there additional investigations utilizing F18 Florbetapir (amyvid) cardiac PET/CT imaging?

"Presently, there are 3 active tests assessing the efficacy of F18 Florbetapir (amyvid) cardiac PET/CT imaging. None have yet entered Phase 3. 8 medical sites across Ladera Ranch, California are conducting these investigations."

Answered by AI

Are there any open positions in this experiment for volunteers?

"Affirmative, the information provided on clinicaltrials.gov reveals that this medical trial is still recruiting subjects. This investigation was originally published in October 2020 and underwent its last revision in August 2021 with a target of 10 participants from 1 institution."

Answered by AI

To what extent is the trial pool populated?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, which was initially posted on October 1st 2020 is still actively enrolling participants. 10 volunteers are being sought after in a single location."

Answered by AI
~1 spots leftby May 2025